+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective



AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective



Transfusion and Apheresis Science 37(1): 63-70



The intermediate to high grade B-cell non-Hodgkin lymphomas are now one of three malignant AIDS defining conditions. The others being Kaposi's sarcoma and cervical carcinoma. While co-infection with oncogenic agents including the human herpes 8 or Epstein-Barr virus offer targets in preventive treatment strategies for these AIDS defining lymphomas (ADL), administration of highly active antiretroviral therapy leading to immune reconstitution permits use of standard or even high-dose cytotoxic drug regimens with curative intent. It is not certain whether this should be done concomitantly or sequentially. Additional benefit may derive from infusional or high-dose chemotherapy regimens depending on the histological subtype while use of monoclonal antibodies such as rituximab or immunohaematopoietic stem cell transplantation needs to be further evaluated within controlled studies. Socio-economic considerations have an impact especially in resource limited settings while availability of tools for appropriate geno-phenotypic diagnosis and immunological monitoring such as the CD4 cell count will play an important role in the risk stratification as well as disease management. While it is generally accepted that the impact of HAART has an overall benefit both in incidence and treatment outcome in ADL, the expanded access to HAART programs are falling short of all targets in Africa. Accordingly focus is given to some of these controversies, including epidemiology, pathogenesis, clinical features, therapeutic options and ethical considerations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 020646510

Download citation: RISBibTeXText

PMID: 17931978

DOI: 10.1016/j.transci.2007.04.010


Related references

Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: a case-control study. Sexually Transmitted Infections 76(2): 145-B-146, 2000

Effects of the introduction of highly active antiretroviral therapy (HAART) on the temporal trend of diagnosis of AIDS and AIDS-defining disorders. Le Infezioni in Medicina 8(3): 134-138, 2000

AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART). Current HIV Research 5(5): 484-489, 2007

Aids-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (Haart). Current Hiv Research 5(5): 484-489, 2007

Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leukemia and Lymphoma 41(1-2): 105-116, 2001

The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. Journal of Infection 42(2): 134-139, 2001

AIDS and cancer in the era of highly active antiretroviral therapy (HAART). European Journal of Cancer 37(10): 1316-1319, 2001

AIDS associated cancers in the era of highly active antiretroviral therapy (HAART). Przeglad Epidemiologiczny 61(3): 529-534, 2007

Adherence to highly active antiretroviral therapy (HAART) in HIV/AIDS patient. Acta Medica Indonesiana 46(4): 273-274, 2014

Highly active antiretroviral therapy (HAART) in the patients with HIV infection and AIDS. Zhonghua Pifuke Zazhi 36(7): 387-390, 2003

Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. Plos one 11(2): E0148100, 2016

A Comparison of the Diabetes Risk Score in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) and HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. Plos one 11(5): E0155560, 2016

Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Brazilian Journal of Infectious Diseases 13(2): 130-136, 2009

Meningiomatosis in an AIDS Patient Receiving Highly Active Antiretroviral Therapy (HAART). Neurologist 21(3): 44-46, 2016

The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. American Journal of Epidemiology 165(10): 1143-1153, 2007